NICOTROL (nicotine) by Pfizer is pharmacologic action nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. First approved in 1997.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
NICOTROL is a nicotine inhalant approved in 1997 for smoking cessation, delivering the active alkaloid via oral inhalation to bind stereo-selectively to nicotinic-cholinergic receptors in the central and peripheral nervous system. The drug exerts stimulant effects in the cortex and reward effects in the limbic system, with dopamine and other neurohormonal pathways driving its anti-craving efficacy. It is indicated for adults seeking to quit smoking tobacco.
Product is in late-stage lifecycle with moderate Part D utilization, signaling a maturing brand with likely reduced commercial team investment.
Pharmacologic Action Nicotine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Nicotine Influence on the Retina Following the Use of Electronic Cigarette
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Worked on NICOTROL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNICOTROL represents a mature, late-lifecycle product with minimal linked career opportunities (0 active postings), reflecting lower commercial investment and smaller team footprint. Working on this product offers stability and deep expertise in nicotine replacement and smoking cessation, but limited growth trajectory or high-visibility launch experience.